Rare inherited kidney diseases: Challenges, opportunities, and perspectives

The Lancet

Volumn 383, Issue 9931, 2014, Pages 1844-1859

  Devuyst, Olivier ^a,b   Knoers, Nine V A M ^c   Remuzzi, Giuseppe ^d   Schaefer, Franz ^e  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ECULIZUMAB; ABATACEPT; MERCAPTAMINE; MONOCLONAL ANTIBODY;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; GENE SEQUENCE; GENETIC DISORDER; HEALTH CARE POLICY; HETEROZYGOTE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MEDICAL RESEARCH; NEPHROLITHIASIS; NONHUMAN; ONTOLOGY; ORGANISMS; PRIORITY JOURNAL; REVIEW; ARTICLE; BIOMICS; COHORT ANALYSIS; DISEASE MODEL; GENE ONTOLOGY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SCREENING; GLOMERULOSCLEROSIS; NEXT GENERATION SEQUENCING; PATIENT CARE; RARE DISEASE; RENOVASCULAR DISEASE; RENOVASCULAR HYPERTENSION;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC DISEASES, INBORN; HETEROZYGOTE; HUMANS; KIDNEY DISEASES; RARE DISEASES; RENAL REPLACEMENT THERAPY;

EID: 84901236529     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60659-0     Document Type: Review

References (100)

1. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008; 371: 2039-41.
2. Hayashi S, Umeda T. 35 years of Japanese policy on rare diseases. Lancet 2008; 372: 889-90.
3. Liu BC, He L, He G, He Y. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. J Public Health Policy 2010; 31: 407-20.
4. Soliman NA. Orphan Kidney Diseases. Nephron Clin Pract 2012; 120: c194-99.
5. Orphanet Report Series: Prevalence of rare diseases. November 2013. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence-of-rare-diseases-by- decreasing-prevalence-or-cases.pdf (accessed March 31, 2014).
6. Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development. Profile of rare diseases. Field MJ, Boat TF, eds. Rare diseases and orphan products: accelerating research and development. Washington, DC: National Academies Press, 2010. http://www.ncbi.nlm.nih.gov/books/NBK56184/ (accessed March 31, 2014).
7. Devuyst O, Meij I, Jeunemaitre X, et al, for the EUNEFRON consortium. EUNEFRON, the European Network for the Study of Orphan Nephropathies. Nephrol Dial Transplant 2009; 24: 2011-15.
8. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382: 158-69.
9. Jouret F, Bernard A, Hermans C, et al. Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J Am Soc Nephrol 2007; 18: 707-18.
10. Boyer O, Nevo F, Plaisier E, et al. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N Engl J Med 2011; 365: 2377-88.
11. Kantarci S, Al-Gazali L, Hill RS, et al. Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo- acoustico-renal syndromes. Nat Genet 2007; 39: 957-59.
12. Emma F, Bertini E, Salviati L, Montini G. Renal involvement in mitochondrial cytopathies. Pediatr Nephrol 2012; 27: 539-50.
13. Reeders ST, Breuning MH, Davies KE, et al. A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16. Nature 1985; 317: 542-44.
14. Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990; 248: 1224-27.
15. Rosenthal W, Seibold A, Antaramian A, et al. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature 1992; 359: 233-35.
16. The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 1994; 77: 881-94.
17. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79: 407-14.
18. Lloyd SE, Pearce SH, Fisher SE, et al. A common molecular basis for three inherited kidney stone diseases. Nature 1996; 379: 445-49.
19. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996; 12: 24-30.
20. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 1996; 13: 183-88.
21. Town M, Jean G, Cherqui S, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 1998; 18: 319-24.
22. Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24: 349-54.
23. Hart TC, Gorry MC, Hart PS, et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 2002; 39: 882-92.
24. Otto EA, Hurd TW, Airik R, et al. Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet 2010; 42: 840-50.
25. Tory K, Menyhárd DK, Woerner S, et al. Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome. Nat Genet 2014; 46: 299-304.
26. Morello JP, Salahpour A, Laperrière A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000; 105: 887-95.
27. Syres K, Harrison F, Tadlock M, et al. Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood 2009; 114: 2542-52.
28. Hildebrandt F. Genetic kidney diseases. Lancet 2010; 375: 1287-95.
29. Ji W, Foo JN, O'Roak BJ, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008; 40: 592-99.
30. Rogowski WH, Grosse SD, Khoury MJ. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 2009; 10: 489-95.
31. Scott J, Trotter T. Primary care and genetics and genomics. Pediatrics 2013; 132 (suppl 3): S231-37.
32. Gadegbeku CA, Gipson DS, Holzman LB, et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 2013; 83: 749-56.
33. Seyberth HW, Schlingmann KP. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol 2011; 26: 1789-802.
34. Denamur E, Delezoide AL, Alberti C, et al, for the Société Française de Foetopathologie. Genotype-phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease. Kidney Int 2010; 77: 350-58.
35. Riveira-Munoz E, Chang Q, Godefroid N, et al, for the Belgian Network for Study of Gitelman Syndrome. Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. J Am Soc Nephrol 2007; 18: 1271-83.
36. Tory K, Lacoste T, Burglen L, et al. High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. J Am Soc Nephrol 2007; 18: 1566-75.
37. Hoefele J, Wolf MT, O'Toole JF, et al. Evidence of oligogenic inheritance in nephronophthisis. J Am Soc Nephrol 2007; 18: 2789-95.
38. Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012; 8: 634-42.
39. Devuyst O, Thakker RV. Dent's disease. Orphanet J Rare Dis 2010; 5: 28.
40. Ly JP, Onay T, Quaggin SE. Mouse models to study kidney development, function and disease. Curr Opin Nephrol Hypertens 2011; 20: 382-90.
41. Eddy AA, López-Guisa JM, Okamura DM, Yamaguchi I. Investigating mechanisms of chronic kidney disease in mouse models. Pediatr Nephrol 2012; 27: 1233-47.
42. Meneton P, Ichikawa I, Inagami T, Schnermann J. Renal physiology of the mouse. Am J Physiol Renal Physiol 2000; 278: F339-51.
43. Yasuda Y, Cohen CD, Henger A, Kretzler M, for the European Renal cDNA Bank (ERCB) Consortium. Gene expression profiling analysis in nephrology: towards molecular definition of renal disease. Clin Exp Nephrol 2006; 10: 91-98.
44. Kamath-Rayne BD, Smith HC, Muglia LJ, Morrow AL. Amniotic fluid: the use of high-dimensional biology to understand fetal well-being. Reprod Sci 2014; 21: 6-19.
45. Hogan MC, Manganelli L, Woollard JR, et al. Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol 2009; 20: 278-88.
46. Dear JW, Street JM, Bailey MA. Urinary exosomes: a reservoir for biomarker discovery and potential mediators of intrarenal signalling. Proteomics 2013; 13: 1572-80.
47. Zhou H, Kajiyama H, Tsuji T, et al. Urinary exosomal Wilms' tumor-1 as a potential biomarker for podocyte injury. Am J Physiol Renal Physiol 2013; 305: F553-59.
48. Alkhalaf A, Zürbig P, Bakker SJ, et al, for the PREDICTIONS Group. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010; 5: e13421.
49. Ling XB, Sigdel TK, Lau K, et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J Am Soc Nephrol 2010; 21: 646-53.
50. Drube J, Schiffer E, Lau E, et al. Urinary proteome analysis to exclude severe vesicoureteral reflux. Pediatrics 2012; 129: e356-63.
51. Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 2009; 29: 749-54.
52. Lv LL, Cao YH, Ni HF, et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol Renal Physiol 2013; 305: F1220-27.
53. Zhang A, Sun H, Wu X, Wang X. Urine metabolomics. Clin Chim Acta 2012; 414: 65-69.
54. Vilasi A, Cutillas PR, Maher AD, et al. Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome. Am J Physiol Renal Physiol 2007; 293: F456-67.
55. Desai AN, Jere A. Next-generation sequencing: ready for the clinics? Clin Genet 2012; 81: 503-10.
56. Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell 2013; 155: 27-38.
57. Artuso R, Fallerini C, Dosa L, et al. Advances in Alport syndrome diagnosis using next-generation sequencing. Eur J Hum Genet 2012; 20: 50-57.
58. McCarthy HJ, Bierzynska A, Wherlock M, et al, for the RADAR the UK SRNS Study Group. Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2013; 8: 637-48.
59. Otto EA, Ramaswami G, Janssen S, et al, for the GPN Study Group. Mutation analysis of 18 nephronophthisis associated ciliopathy disease genes using a DNA pooling and next generation sequencing strategy. J Med Genet 2011; 48: 105-16.
60. Shapiro E, Biezuner T, Linnarsson S. Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat Rev Genet 2013; 14: 618-30.
61. Baker M. Big biology: the 'omes puzzle. Nature 2013; 494: 416-19.
62. Köhler S, Doelken SC, Mungall CJ, et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res 2014; 42: D966-74.
63. Jouret F, Walrand S, Parreira KS, et al. Single photon emission-computed tomography (SPECT) for functional investigation of the proximal tubule in conscious mice. Am J Physiol Renal Physiol 2010; 298: F454-60.
64. Schreiber A, Shulhevich Y, Geraci S, et al. Transcutaneous measurement of renal function in conscious mice. Am J Physiol Renal Physiol 2012; 303: F783-88.
65. Grubb SC, Bult CJ, Bogue MA. Mouse Phenome Database. Nucleic Acids Res 2013; 42: D825-34.
66. Zheng S, Geghman K, Shenoy S, Li C. Retake the center stage-new development of rat genetics. J Genet Genomics 2012; 39: 261-68.
67. Brown AJ, Fisher DA, Kouranova E, et al. Whole-rat conditional gene knockout via genome editing. Nat Methods 2013; 10: 638-40.
68. Drummond IA. Kidney development and disease in the zebrafish. J Am Soc Nephrol 2005; 16: 299-304.
69. Drummond I. Studying cilia in zebrafish. Methods Cell Biol 2009; 93: 197-217.
70. Zhou W, Hildebrandt F. Inducible podocyte injury and proteinuria in transgenic zebrafish. J Am Soc Nephrol 2012; 23: 1039-47.
71. Mahmood F, Mozere M, Zdebik AA, et al. Generation and validation of a zebrafish model of EAST (epilepsy, ataxia, sensorineural deafness and tubulopathy) syndrome. Dis Model Mech 2013; 6: 652-60.
72. Weavers H, Prieto-Sánchez S, Grawe F, et al. The insect nephrocyte is a podocyte-like cell with a filtration slit diaphragm. Nature 2009; 457: 322-26.
73. Zhang F, Zhao Y, Chao Y, Muir K, Han Z. Cubilin and amnionless mediate protein reabsorption in Drosophila nephrocytes. J Am Soc Nephrol 2013; 24: 209-16.
74. Müller RU, Zank S, Fabretti F, Benzing T. Caenorhabditis elegans, a model organism for kidney research: from cilia to mechanosensation and longevity. Curr Opin Nephrol Hypertens 2011; 20: 400-08.
75. Beets I, Janssen T, Meelkop E, et al. Vasopressin/oxytocin-related signaling regulates gustatory associative learning in C. elegans. Science 2012; 338: 543-45.
76. Devuyst O, Antignac C, Bindels RJ, et al. The ERA-EDTA Working Group on inherited kidney disorders. Nephrol Dial Transplant 2012; 27: 67-69.
77. Tong A, Wong G, Hodson E, Walker RG, Tjaden L, Craig JC. Adolescent views on transition in diabetes and nephrology. Eur J Pediatr 2013; 172: 293-304.
78. Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O. The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 2011; 80: 338-47.
79. Trudu M, Janas S, Lanzani C, et al, for the Swiss Kidney Project on Genes in Hypertension (SKIPOGH) team. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med 2013; 19: 1655-60.
80. Böger CA, Chen MH, Tin A, et al, for the CKDGen Consortium. CUBN is a gene locus for albuminuria. J Am Soc Nephrol 2011; 22: 555-70.
81. Chasman DI, Fuchsberger C, Pattaro C, et al, for the CARDIoGRAM Consortium and the ICBP Consortium and the CARe Consortium and the WTCCC2. Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Hum Mol Genet 2012; 21: 5329-43.
82. 2+ handling, is mutated in dominant hypomagnesemia. Am J Hum Genet 2011; 88: 333-43.
83. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-87.
84. Gbadegesin RA, Winn MP, Smoyer WE. Genetic testing in nephrotic syndrome-challenges and opportunities. Nat Rev Nephrol 2013; 9: 179-84.
85. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013; 369: 649-58.
86. Jézégou A, Llinares E, Anne C, et al. Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. Proc Natl Acad Sci USA 2012; 109: E3434-43.
87. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-33.
88. Robben JH, Kortenoeven ML, Sze M, et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci USA 2009; 106: 12195-200.
89. Brodin-Sartorius A, Tête MJ, Niaudet P, et al. Cysteamine therapy elays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int 2012; 81: 179-89.
90. Cravedi P, Kopp JB, Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant 2013; 13: 266-74.
91. Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013; 369: 2416-23.
92. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V, for the French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-57.
93. Lemaire M, Frémeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45: 531-36.
94. Takahashi K, Makita N, Manaka K, et al. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists. J Biol Chem 2012; 287: 2099-106.
95. Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006; 17: 232-43.
96. Bolignano D, Nagler EV, Van Biesen W, Zoccali C. Providing guidance in the dark: rare renal diseases and the challenge to improve the quality of evidence. Nephrol Dial Transplant 2013; published online Sept 11. DOI:10.1093/ndt/gft344.
97. Forman J, Taruscio D, Llera VA, et al, for the International Conference for Rare Diseases and Orphan Drugs (ICORD). The need for worldwide policy and action plans for rare diseases. Acta Paediatr 2012; 101: 805-07.
98. Schlingmann KP, Kaufmann M, Weber S, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011; 365: 410-21.
99. Aymé S, Kole A, Groft S. Empowerment of patients: lessons from the rare diseases community. Lancet 2008; 371: 2048-51.
100. Ingelfinger JR, Drazen JM. Patient organizations and research on rare diseases. N Engl J Med 2011; 364: 1670-71.